Chennai, October 14, 2022: AstraZeneca India Private Limited, the global capability centre of leading science-led biopharmaceutical company AstraZeneca, plans to further expand its Clinical Data and Insights (CDI) division after the new unit tripled its headcount within its first year of launch in Bengaluru. To accommodate this expansion, the Bengaluru centre recently leased additional space that is being inaugurated today by key global leaders.
The continued investment will include hiring additional data experts and deepening the role that India plays in supporting and driving AstraZeneca’s growing portfolio of new medicines by further strengthening the management of global clinical data. It works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3 with an integrated end-to-end approach for clinical data, analytics, insights and risk management.
The CDI division today has over one hundred employees (Data managers, Programmers, Data Scientists, Data Standards experts), compared with a headcount of 30 at its official launch in October 2021, forming part of a global network spread across 6 countries.
Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited (AZIPL) said, “I am delighted to see the growth, the CDI division has exhibited within the first year of inception. Today, with over 100 employees, the Bengaluru team is strategically supporting the global trials, and will further strengthen its role in supporting AstraZeneca's aspiration to be pioneer in science and transform patient outcomes.”
Natalie Fishburn, Vice President, Global Head of CDI, AstraZeneca, said, “I am very proud of CDI’s journey in India and the work the teams have accomplished from here. AstraZeneca’s global CDI footprint is a strong ecosystem with over 1300 employees and vendor partner resources that closely collaborate in an effort towards transforming our clinical data flows and advance data-derived insights, enabling acceleration of life-changing medicines to patients.”
Ram Mudaliar, CDI India Lead, AstraZeneca India Private Limited, said, “The way in which we leverage data is evolving, and the CDI division in India is playing a key role in managing clinical data at exponential volume, scale, and complexity. We are growing and expanding our capabilities to be ready for the future. Given the availability of niche talent in India, we are confident of establishing Bengaluru as a centre of data excellence for AstraZeneca.”
The CDI division in Bengaluru is a critical advancement to support a growing global portfolio and build on internal data expertise. In addition to Data Management and Data Standards, functions like Centralized Monitoring, TRISARC (Trials Safety Review Centre) and SASP comprising of safety patient data review experts are also setting up their teams in the Bengaluru centre.
About AstraZeneca India Private Limited
AstraZeneca India Pvt. Ltd. (AZIPL) is the services arm of AstraZeneca with offices in Chennai and Bengaluru. The entity has close to 3000 employees catering to services including IT services, Global Business Services (GBS) and R&D Oncology among others. It plays a key role in technology innovation and transformation projects enabling and empowering AstraZeneca’s core business processes – from Discovery, Development, Production, and Launches to Supply all the way through the value chain. www.astrazeneca.com/india
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases across our main disease areas: Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease. AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
No comments:
Post a Comment